&nbsp;

PSQIHealthEquityReportSlideshow.pptx

Mar 2018

Document

PSQIHealthEquityReportTechnicalAppendix.pdf

Mar 2018

Document

PSQI_2018.pptx

Apr 2018

Document

PSQIExecutiveSummary.pdf

Apr 2018

Document

PSQI_FullReport.pdf

Apr 2018

Document

PatientExperienceSocialAds.zip

Apr 2018

Drug

pegaspargase

Other Name(s): Oncaspar®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Dec 2022

Guidelines and Advice

Position Statements for Nursing Practice in Cancer Care

Status: Current
Version: 2

May 2021

Guidelines and Advice

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2017

Status: Current
ID: PET 2017-2
Version: n/a

May 2018

Regimen

GCVP+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Curative

Funding:

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

GCVP+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

, Collapse Show fewer tags

Drugs Used:

riTUXimab (Unfunded),

riTUXimab (subcut) (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

PEME+PEMB(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)